Skip to content
lifestyle.wordsjournal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cullinan Therapeutics, Inc.
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 21, 2026
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
September 14, 2026
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
September 10, 2026
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
July 28, 2026
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 10, 2026
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
February 18, 2026
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 10, 2026